Mycobacterium tuberculosis infection

AC A8 A08.001 Signal peptidase II Drug target for Mycobacterium tuberculosis infection... 

Abel, B., et al., Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice, J. Immunol. 169, 6, 3155, 2002. 

Colston MJ et al (2004) Antimycobacterial calixarenes enhance innate defense mechanisms in murine macrophages and induce control of Mycobacterium tuberculosis infection in mice. Infect Immun 72 6318-6323... 

This process was undoubtedly developed for the manufacture of pyrazinamide (Zinamide, etc.),1696 a second-line drug for Mycobacterium tuberculosis infections, resistant to more effective and less toxic agents. Thus a mixture of 2-methyl-pyrazine (323), ammonia, oxygen, and steam is passed (at 400°C) over an alumina- or pumice-supported catalyst comprising one to three oxides of Ce, Cr, Mo, Mn, P, Sb, Ti, or (most importantly) V the main product (in up to 90% yield) is 2-pyrazinecarbonitrile (324), easily converted into 2-pyrazinecarboxamide... 

Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidmg-resistant Mycobacterium tuberculosis infections Eactors in transmission to staff and HIV-infected patients. JAMA 1992 268 1280-1286. 

Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, Flynn JL. Abata-cept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 2007 56 2557-2565. 

Carl A. Machutta was born on 12 June 1979 in Levittown, NY. He obtained his B.S. in biochemistry and Ph.D. in chemistry at Stony Brook University under the mentorship of Professor Peter J. Tonge. He is currently a postdoctoral associate in this laboratory and his research has focused on the biophysical, kinetic, and structural characterization of protein drug targets as well as their inhibition mechanism. Currendy, interligand NOE NMR, a fragment-based approach, is being utilized to rationally modify a lead compound for the development of novel chemotherapeutics for Mycobacterium tuberculosis infection. 

Andersen, P. 1994, Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infection Immunity 62 2536-2544. 

Pedrosa J, Saunders BM, Appelbeig R, Orme IM, Silva MT, Cooper AM Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect Immun 2000 68 577-583. 

Barrow EL, Winchester GA, Staas JK, Quenelle DC, Barrow WW. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrobial Agents and Chemotherapy. October 1998 42(10) 2682-2689. PubMed PMID 9756777. Pubmed Central PMCID 105919. 

Lin Y, Zhang M, Bames PF. Chemokine production by a human alveolar epithelial cell line in response to Mycobacterium tuberculosis. Infect Immun 1998 66 1121-1126. 

Meddows-Taylor S, Martin DJ, Tiemessen CT. Dysregulated production of interleukin-8 in individuals infected with human immunodeficiency virus type 1 and Mycobacterium tuberculosis. Infect Inunun 1999 67 1251-1260. 

The utility of using DO mice to model human disease and population-level responses has been demonstrated in recent manuscripts. As with CC mice, DO mice have been employed as a tool to study a variety of human conditions, including pain sensitivity (Recla et al., 2014), development of atherosclerosis (Smallwood et al., 2014), susceptibility to Mycobacterium tuberculosis infection (Harrison et al., 2014), and neurobehavioral traits (Logan et al., 2013), including addiction to drugs of abuse (Dickson et al., 2015). 

Wolf AJ, Linas B, Trevejo-Nunez GJ, Kincaid E, Tamura T, Takatsu K, Ernst JD (2007) Mycobacterium tuberculosis infects dendritic cells with high liequency and impairs their function in vivo. J Immunol 179 2509 2519... 

Murphy DJ, Brown JR (2007) Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect Dis 7 84... 

Yehia BR, Blumberg EA. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl 2010 16 1129-35. 

Infection with Mycobacterium tuberculosis and a variety of non-tuberculous mycobacteria has been observed in HSC transplant recipients (Navari et al. 1983 Mohite et al. 2001). Mycobacterium tuberculosis infection can occur after HSC transplantation, but the incidence in the reported series is lower than that of other infections (Roy and Weisdorf 1997 Aljurf et al. 1999 Mohite et al. 2001). Overall, the incidence of tuberculosis has bee reported to be between 0.19% and 5.5% of cases (Martino et al. 1996 Roy and Weisdorf 1997). Reports of non-tuberculous mycobacterial disease in both HSC and solid organ transplant recipients have also increased (Ozkaynak et al. 1990 Busch et al. 1991 Doucette and Fishman 2004). 

Aljurf M, Gyger M, Alrajhi A, Sahovic E, Chaudhri N, Musa M, Ayoub O, Seth P, Aslam M, Al-Fiar F (1999) Mycobacterium tuberculosis infection in allogeneic bone marrow transplantation patients. Bone Marrow Transplant 24 551-554... 

Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. lL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995 155(5) 2515-2524. 

Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999 67(4) 1702-1707. 

---